Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Raju Mohan
|
| gptkbp:clinicalTrialPhase |
Phase 1 (VTX3232)
Phase 2 (VTX002) Phase 2 (VTX2735) Phase 2 (VTX958) |
| gptkbp:developedBy |
small molecule therapeutics
|
| gptkbp:focusesOn |
immunology
inflammatory diseases |
| gptkbp:foundedYear |
2018
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ventyx Biosciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
VTX002
VTX2735 VTX3232 VTX958 |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
VTYX
|
| gptkbp:therapeuticArea |
autoimmune diseases
psoriasis rheumatoid arthritis inflammatory bowel disease |
| gptkbp:website |
https://www.ventyxbio.com/
|
| gptkbp:bfsParent |
gptkb:The_Column_Group
|
| gptkbp:bfsLayer |
7
|